New
Clinuvel Pharmaceuticals, drug developer for skin diseases from Melbourne, has received an unsolicited $95 million takeover offer from a controversial biotech company Retrophin, soon after sudden passing of Clinuvel's long time director Jack Wood.
On behalf of VRF management, we offer our sincere condolences to Jack's wife and family. Jack Wood was a remarkable person with a vision, big heart and brilliant sense of humor. Clinuvel is awaiting clearance from the European drug regulator for the use of its drug Scenesse in the treatment of a rare skin disease Erythropoietic Protoporphyria and potentially, in vitiligo.
Once a notorious short seller with loud public pressure, Reptophin's CEO Martin Shkreli now aims at drugs for ultra-rare and dangerous conditions. Clinuvel has appointed an advisory firm in the defense against the hostile offer.
FAQOther Questions
- Pyrostegia venusta as a folk medicine for vitiligo?
Pyrostegia venusta is a neotropical evergreen vine widely spread in Brazil throughout fields, at the coast, edge of the woods and along roadsides (see photo below). Popularly kn...
- Is vitiligo contagious?
Vitiligo is NOT contagious. It cannot be passed on or caught from touching someone with vitiligo, shaking hands, swimming in the same pool, sharing towels, sitting next to someo...
- What are risks of oral and topical corticosteroids?
Corticosteroid drugs (like hydrocortisone, and others) are often used for treating vitiligo. By mimicing the effects of hormones your body produces naturally in your adrenal gla...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.